US20090170867A1 - Trpv1 antagonists including sulfonamide substituent and uses thereof - Google Patents

Trpv1 antagonists including sulfonamide substituent and uses thereof Download PDF

Info

Publication number
US20090170867A1
US20090170867A1 US12/110,089 US11008908A US2009170867A1 US 20090170867 A1 US20090170867 A1 US 20090170867A1 US 11008908 A US11008908 A US 11008908A US 2009170867 A1 US2009170867 A1 US 2009170867A1
Authority
US
United States
Prior art keywords
halo
alkyl
another embodiment
compound
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/110,089
Other languages
English (en)
Inventor
Noriyuki Kurose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to US12/110,089 priority Critical patent/US20090170867A1/en
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUROSE, NORIYUKI
Publication of US20090170867A1 publication Critical patent/US20090170867A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention relates to compounds of formula I, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I.
  • Pain is the most common symptom for which patients seek medical advice and treatment. Pain can be acute or chronic. While acute pain is usually self-limited, chronic pain persists for 3 months or longer and can lead to significant changes in a patient's personality, lifestyle, functional ability and overall quality of life (K. M. Foley, Pain , in Cecil Textbook of Medicine 100-107 (J. C. Bennett and F. Plum eds., 20th ed. 1996)).
  • Nociceptive pain includes tissue injury-induced pain and inflammatory pain such as that associated with arthritis.
  • Neuropathic pain is caused by damage to the peripheral or central nervous system and is maintained by aberrant somatosensory processing.
  • vanilloid receptors V. Di Marzo et al., Current Opinion in Neurobiology 12:372-379 (2002)
  • Nociceptive pain has been traditionally managed by administering non-opioid analgesics, such as acetylsalicylic acid, choline magnesium trisalicylate, acetaminophen, ibuprofen, fenoprofen, diflusinal, and naproxen; or opioid analgesics, including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone.
  • opioid analgesics including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone.
  • neuropathic pain which can be difficult to treat, has also been treated with anti-epileptics (e.g., gabapentin, carbamazepine, valproic acid, topiramate, phenyloin), NMDA antagonists (e.g., ketamine, dextromethorphan), topical lidocaine (for post-herpetic neuralgia), and tricyclic antidepressants (e.g., fluoxetine, sertraline and amitriptyline).
  • anti-epileptics e.g., gabapentin, carbamazepine, valproic acid, topiramate, phenyloin
  • NMDA antagonists e.g., ketamine, dextromethorphan
  • topical lidocaine for post-herpetic neuralgia
  • tricyclic antidepressants e.g., fluoxetine, sertraline and amitriptyline
  • UI uncontrollable urination, generally caused by bladder-detrusor-muscle instability.
  • UI affects people of all ages and levels of physical health, both in health care settings and in the community at large.
  • Physiologic bladder contraction results in large part from acetylcholine-induced stimulation of post-ganglionic muscarinic-receptor sites on bladder smooth muscle.
  • Treatments for UI include the administration of drugs having bladder-relaxant properties, which help to control bladder-detrusor-muscle overactivity.
  • Antacids such as aluminum hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium bicarbonate can be used to neutralize stomach acids. Antacids, however, can cause alkalosis, leading to nausea, headache, and weakness. Antacids can also interfere with the absorption of other drugs into the blood stream and cause diarrhea.
  • H 2 antagonists such as cimetidine, ranitidine, famotidine, and nizatidine are also used to treat ulcers. H 2 antagonists promote ulcer healing by reducing gastric acid and digestive-enzyme secretion elicited by histamine and other H 2 agonists in the stomach and duodenum. H 2 antagonists, however, can cause breast enlargement and impotence in men, mental changes (especially in the elderly), headache, dizziness, nausea, myalgia, diarrhea, rash, and fever.
  • H + , K + -ATPase inhibitors such as omeprazole and lansoprazole are also used to treat ulcers.
  • H + , K + -ATPase inhibitors inhibit the production of enzymes used by the stomach to secrete acid.
  • Side effects associated with H + , K + -ATPase inhibitors include nausea, diarrhea, abdominal colic, headache, dizziness, somnolence, skin rashes, and transient elevations of plasma activities of aminotransferases.
  • IBD Inflammatory-bowel disease
  • Crohn's disease which can include regional enteritis, granulomatous ileitis, and ileocolitis, is a chronic inflammation of the intestinal wall. Crohn's disease occurs equally in both sexes and is more common in Jews of eastern-European ancestry. Most cases of Crohn's disease begin before age 30 and the majority start between the ages of 14 and 24. The disease typically affects the full thickness of the intestinal wall. Generally the disease affects the lowest portion of the small intestine (ileum) and the large intestine, but can occur in any part of the digestive tract.
  • Ulcerative colitis is a chronic disease in which the large intestine becomes inflamed and ulcerated, leading to episodes of bloody diarrhea, abdominal cramps, and fever. Ulcerative colitis usually begins between ages 15 and 30; however, a small group of people have their first attack between ages 50 and 70. Unlike Crohn's disease, ulcerative colitis never affects the small intestine and does not affect the full thickness of the intestine. The disease usually begins in the rectum and the sigmoid colon and eventually spreads partially or completely throughout the large intestine. The cause of ulcerative colitis is unknown.
  • ulcerative colitis Treatment of ulcerative colitis is directed to controlling inflammation, reducing symptoms, and replacing lost fluids and nutrients.
  • Anticholinergic drugs and low doses of diphenoxylate or loperamide are administered for treating mild diarrhea. For more intense diarrhea higher doses of diphenoxylate or loperamide, or deodorized opium tincture or codeine are administered.
  • IBS Irritable-bowel syndrome
  • IBS Irritable-bowel syndrome
  • stimuli such as stress, diet, drugs, hormones, or irritants can cause the gastrointestinal tract to contract abnormally.
  • contractions of the gastrointestinal tract become stronger and more frequent, resulting in the rapid transit of food and feces through the small intestine, often leading to diarrhea.
  • Cramps result from the strong contractions of the large intestine and increased sensitivity of pain receptors in the large intestine.
  • IBS IBS-patient's diet
  • an IBS patient avoid beans, cabbage, sorbitol, and fructose.
  • a low-fat, high-fiber diet can also help some IBS patients.
  • Regular physical activity can also help keep the gastrointestinal tract functioning properly.
  • Drugs such as propantheline that slow the function of the gastrointestinal tract are generally not effective for treating IBS.
  • Antidiarrheal drugs such as diphenoxylate and loperamide, help with diarrhea. The Merck Manual of Medical Information 525-526 (R. Berkow ed., 1997).
  • U.S. Pat. No. 5,891,889 describes a class of substituted piperidine compounds that are useful as inhibitors of farnesyl-protein transferase, and the farnesylation of the oncogene protein Ras.
  • Japanese patent application no. 11-199573 to Kiyoshi et al. describes benzothiazole derivatives that are neuronal 5HT3 receptor agonists in the intestinal canal nervous system and useful for treating digestive disorders and pancreatic insufficiency.
  • German patent application no 199 34 799 to Rainer et al. describes a chiral-smectic liquid crystal mixture containing compounds with 2 linked (hetero)aromatic rings or compounds with 3 linked (hetero)aromatic rings.
  • the invention encompasses compounds of formula I:
  • X is O, S, N—CN, N—OH, or N—OR 10 ;
  • W is N or C
  • R 4 is absent, otherwise R 4 is —H, —OH, —OCF 3 , -halo, —(C 1 -C 6 )alkyl, —CH 2 OH, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 F, —CH(halo) 2 , —CF 3 , —OR 10 , —SR 10 , —COOH, —COOR 10 , —C(O)R 10 , —C(O)H, —OC(O)R 10 , —OC(O)NHR 10 , —NHC(O)R 13 , —CON(R 13 ) 2 , —S(O) 2 R 10 , or —NO 2 ;
  • R 10 is —(C 1 -C 4 )alkyl
  • each R 13 is independently —H, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkenyl, —(C 1 -C 4 )alkynyl, or -phenyl;
  • c is the integer 0, 1, or 2;
  • Y 1 , Y 2 , Y 3 are independently C, N, or O;
  • Y 1 , Y 2 , or Y 3 can be O, and for each Y 1 , Y 2 , and Y 3 that is N, the N is bonded to one R 21 group, and for each Y 1 , Y 2 , and Y 3 that is C, the C is bonded to two R 20 groups, provided that there are no more than a total of two (C 1 -C 6 )alkyl groups substituted on all of Y 1 , Y 2 , and Y 3 ;
  • R 12a and R 12b are independently —H or —(C 1 -C 6 )alkyl
  • E is ⁇ O, ⁇ S, ⁇ CH(C 1 -C 5 )alkyl, ⁇ CH(C 1 -C 5 )alkenyl, —NH(C 1 -C 6 )alkyl, or ⁇ N—OR 20 ;
  • R 1 is —H, -halo, —(C 1 -C 4 )alkyl, —NO 2 , —CN, —OH, —OCH 3 , —NH 2 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
  • each R 2 is independently:
  • Z 1 is —H, —OR 7 , —SR 7 , —CH 2 —OR 7 , —CH 2 —SR 7 , —CH 2 —N(R 20 ) 2 , or -halo;
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —CH 2 —OR 7 , -phenyl, or -halo;
  • each Z 3 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or -phenyl;
  • Z 4 is —H, —OH, —OR 20 , —(C 1 -C 6 )alkyl, or —N(R 20 ) 2 ;
  • J is —OR 20 , —SR 20 , —N(R 20 ) 2 , or —CN;
  • R 2 group is a group of formula Q, and provided that when Z 1 is —OR 7 or —SR 7 , then Z 2 is not -halo;
  • each R 3 is independently:
  • R a is —H, —(C 1 -C 6 )alkyl, —(C 3 -C 8 )cycloalkyl, —CH 2 —C(O)—R c , —(CH 2 )—C(O)—OR c , —(CH 2 )—C(O)—N(R) 2 , —(CH 2 ) 2 —O—R c , —(CH 2 ) 2 —S(O) 2 —N(R) 2 , or —(CH 2 ) 2 —N(R c )S(O) 2 —R c ;
  • R b is:
  • each R c is independently —H or —(C 1 -C 4 )alkyl
  • each R 7 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )hydroxyalkyl, —(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-N(R 20 ) 2 , or —CON(R 20 ) 2 ;
  • each R 8 and R 9 is independently:
  • each R 11 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH ⁇ NR 7 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , or —OC(O)OR 7 ;
  • each R 14 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, —(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), -(3- to 7-membered)heterocycle, —(C 1 -C 6 )haloalkyl, —(C 2 -C 6 )haloalkenyl, —(C 2 -C 6 )haloalkynyl, —(C 2 -C 6 )hydroxyalkenyl, —(C 2 -C 6 )hydroxy
  • each R 20 is independently —H, —(C 1 -C 6 )alkyl, or —(C 3 -C 8 )cycloalkyl;
  • each R 21 is independently —H, —(C 1 -C 6 )alkyl
  • each halo is independently —F, —Cl, —Br, or —I;
  • n is the integer 1, 2, or 3;
  • p is the integer 1 or 2;
  • each b is independently the integer 1 or 2;
  • q is the integer 0, 1, 2, 3, or 4;
  • r is the integer 0, 1, 2, 3, 4, 5, or 6;
  • s is the integer 0, 1, 2, 3, 4, or 5;
  • t is the integer 0, 1, 2, or 3;
  • n is the integer 0, 1, or 2.
  • Compounds of formula I are potent at TRPV1 receptors, and are highly soluble in aqueous solutions at either pH 6.8 or pH 1.2.
  • a compound of formula I, or a pharmaceutically acceptable derivative thereof, is useful for treating or preventing pain, UI, an ulcer, IBD, or IBS (each being a “Condition”) in an animal.
  • the invention also relates to compositions comprising an effective amount of a compound of formula I, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier or excipient.
  • compositions are useful for treating or preventing a Condition in an animal.
  • the invention further relates to methods for treating a Condition comprising administering to an animal in need thereof an effective amount of a compound of formula I, or a pharmaceutically acceptable derivative thereof.
  • the invention further relates to use of a compound of formula I in the manufacture of a medicament for treating and/or preventing a Condition.
  • the invention further relates to methods for preventing a Condition comprising administering to an animal in need thereof an effective amount of a compound of formula I, or a pharmaceutically acceptable derivative thereof.
  • the invention still further relates to methods for inhibiting Transient Receptor Potential Vanilloid 1 (“TRPV1,” formerly known as Vanilloid Receptor 1 or VR1) function in a cell, comprising contacting a cell capable of expressing TRPV1 with an effective amount of a compound of formula I, or a pharmaceutically acceptable derivative thereof.
  • TRPV1 Transient Receptor Potential Vanilloid 1
  • the invention still further relates to a method for preparing a composition
  • a method for preparing a composition comprising the step of admixing a compound of formula I, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier or excipient.
  • the invention still further relates to a kit comprising a container containing an effective amount of a compound of formula I, or a pharmaceutically acceptable derivative thereof.
  • compounds of formula I are compounds of formula IA′:
  • compounds of formula I are compounds of formula II:
  • Ar 1 is:
  • R 20 is —H, —(C 1 -C 6 )alkyl, or —(C 3 -C 8 )cycloalkyl;
  • each Z 3 is independently —H or —CH 3 ;
  • R 1 is —Cl, —F, —CF 3 , or —CH 3 ;
  • R 14 is —H, —Cl, —F, —Br, —CF 3 , —OCF 3 , —(C 1 -C 6 )alkyl, —SO 2 CF 3 , —SO 2 (C 1 -C 6 )alkyl, —OCH 3 , —OCH 2 CH 3 , or —OCH(CH 3 ) 2 , and optionally is —H, —CF 3 , —OCF 3 , —Cl, or —F;
  • R 14′ is —H, —Cl, —F, —Br, —CF 3 , —OCF 3 , —(C 1 -C 6 )alkyl, —SO 2 CF 3 , —SO 2 (C 1 -C 6 )alkyl, —OCH 3 , —OCH 2 CH 3 , or —OCH(CH 3 ) 2 , and optionally is —H, —CF 3 , —OCF 3 , —Cl, or —F; and
  • each R 8 and R 9 is independently —H, —Cl, —Br, —F, —CH 3 , —OCH 3 , —OCH 2 CH 3 , —CF 3 , —OCF 3 , iso-propyl, or tert-butyl.
  • FIG. 1 96-well plate with different agonist solutions (Agonist Plate). Seven different sulfuric acid solutions, or agonist solutions, with different sulfuric acid (H 2 SO 4 ) concentrations (of from 15.0 mM to 18 mM as indicated) were used for the pH assay as indicated. For the wells in row A, measuring buffer alone was used. The final concentration of sulfuric acid in the wells for each row, after a 1:4 dilution of the agonist solution, is also indicated in each row in parenthesis.
  • H 2 SO 4 sulfuric acid
  • FIG. 2 pH dependent Ca 2+ responses in TRPV1/CHO cells.
  • Ca 2+ influx into TRPV1/CHO cells as measured by Fura-2 AM fluorescence is indicated by the graph within each rectangular field.
  • the graph presents the fluorescence intensity over time starting from the addition of agonist solution.
  • Each rectangular field presents one experiment performed in one well of a 96-well plate.
  • Each row presents six experiments performed at the same final sulfuric acid concentration; the final sulfuric acid concentration is indicated at the left. Actual pH values were measured after the experiment and are indicated above the graph. No antagonists were added to the cell culture.
  • Final sulfuric acid concentrations of 3.2 and 3.3 mM produced an appropriate Ca 2+ response and were selected for subsequent assays. These final sulfuric acid concentrations can be obtained by 1:4 dilutions of agonist solution with sulfuric acid concentrations of 16.0 mM or 16.5 mM, respectively (see FIG. 1 ).
  • FIG. 3 A 96-well plate with two different sulfuric acid concentrations. Wells in columns 1 to 6 had one final sulfuric acid concentration; wells in columns 7 to 12 had a different final sulfuric acid concentration. The final sulfuric acid concentration was reached by 1:4 dilution of two different agonist solutions with sulfuric acid concentrations of X mM and (X+0.5) mM, respectively. In the experiment described in Section 2 of Protocol 2, X was determined to be 16 mM.
  • B A 96-well plate with different test compound, or antagonist, concentrations indicated in nM. Only one kind of test compound was applied per 96-well plate. Since two different sulfuric acid concentrations were used (columns 1-6 vs.
  • test compound concentration and agonist solution e.g., wells A1, B1, C1, E1, F1, G1, and H1 were tested for test compound concentration 0.977 nM and agonist solution with sulfuric acid solution X mM.
  • wells in row D did not include an antagonist in order to measure the maximal Ca 2+ response.
  • the invention encompasses compounds of formula I:
  • a compound of formula I is a pharmaceutically acceptable derivative of a compound of formula I.
  • a compound of formula I is a compound of formula I wherein the derivative is a pharmaceutically acceptable salt.
  • a compound of formula I is a pharmaceutically acceptable salt of a compound of formula I.
  • Ar 1 is a pyridyl group.
  • Ar 1 is a pyrimidinyl group.
  • Ar 1 is a pyrazinyl group.
  • Ar 1 is pyridazinyl group.
  • W is C.
  • W is N.
  • X is O.
  • X is S.
  • X is N—CN.
  • X is N—OH.
  • X is N—OR 10 .
  • Ar 2 is a benzoimidazolyl group.
  • Ar 2 is a benzothiazolyl group.
  • Ar 2 is a benzooxazolyl group.
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • n or p is 1.
  • n or p is 2.
  • n 3.
  • n 2
  • each R 3 is independently —H, or —(C 1 -C 6 )alkyl.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R 8 groups, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with an R 8 group, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted or substituted with an R 8 group, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge.
  • two R 3 groups together form a (C 2 )bridge, a —HC ⁇ CH— bridge, or a (C 3 )bridge each of which is unsubstituted.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R 8 groups, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with an R 8 group, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted or substituted with an R 8 group, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 )bridge, a —HC ⁇ CH— bridge, or a (C 3 )bridge each of which is unsubstituted, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a —CH 2 —N(R a )—CH 2 — bridge (B1), a
  • R a is —H, —(C 1 -C 6 )alkyl, —(C 3 -C 8 )cycloalkyl, —CH 2 —C(O)—R c , —(CH 2 )—C(O)—OR c , —(CH 2 )—C(O)—N(R c ) 2 , —(CH 2 ) 2 —O—R c , —(CH 2 ) 2 —S(O) 2 —N(R c ) 2 , or —(CH 2 ) 2 —N(R c )S(O) 2 —R c ;
  • R b is:
  • each R c is independently —H or —(C 1 -C 4 )alkyl
  • the B1, B2, or B3 bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups form a bicyclo group to give one of the following structures
  • n 1
  • n 0.
  • s or q is 0.
  • s or q is 1.
  • s or q is 2.
  • R 1 is —H.
  • R 1 is -halo
  • R 1 is —Cl
  • R 1 is —F.
  • R 1 is —CH 3 .
  • R 1 is —NO 2 .
  • R 1 is —CN.
  • R 1 is —OH.
  • R 1 is —OCH 3 .
  • R 1 is —NH 2 .
  • R 1 is —C(halo) 3 .
  • R 1 is —CF 3 .
  • R 1 is —CH(halo) 2 .
  • R 1 is —CH 2 (halo).
  • Ar 1 is a pyridyl group and n is 1.
  • Ar 1 is a pyrazinyl group and p is 1.
  • Ar 1 is a pyrimidinyl group and p is 1.
  • Ar 1 is a pyridazinyl group and p is 1.
  • R 2 when n and p are 1, then R 2 must be Q.
  • Z 1 is —H.
  • Z 1 is —OH.
  • Z 1 is —OCH 3 .
  • Z 1 is —CH 2 OH.
  • Z 2 is —CH 2 —OR 7 .
  • Z 2 is —CH 2 OH.
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo.
  • Z 2 is —H.
  • Z 2 is —CH 3 .
  • Z 3 is —H.
  • Z 3 is —CH 3 .
  • m is 1 and R 3 is —(C 1 -C 6 )alkyl.
  • m is 1 and R 3 is —CH 3 or —CH 2 CH 3 .
  • m is 1 and R 3 is —CH 3 .
  • m is 1 and R 3 is —CH 2 OH.
  • n 0.
  • R 4 is —OH.
  • R 4 is —OCF 3 .
  • R 4 is -halo
  • R 4 is —F.
  • R 4 is —Cl
  • R 4 is —(C 1 -C 6 )alkyl.
  • R 4 is —CH 3 .
  • R 4 is —CH 2 OH.
  • R 4 is —CH 2 Cl.
  • R 4 is —CH 2 Br.
  • R 4 is —CH 2 I.
  • R 4 is —CH 2 F.
  • R 4 is —CH(halo) 2 .
  • R 4 is —CF 3 .
  • R 4 is —NO 2 .
  • R 4 is —OR 10 .
  • R 4 is —SR 10 .
  • R 4 is —C(O)R 10 .
  • R 4 is —COOH
  • R 4 is —C(O)H.
  • R 4 is —COOR 10 .
  • R 4 is —OC(O)R 10 .
  • R 4 is —SO 2 R 10 .
  • R 4 is —OC(O)NHR 10 .
  • R 4 is —NHC(O)R 13 .
  • R 4 is —CON(R 13 ) 2 .
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl.
  • each R 20 is —H.
  • each R 20 is —(C 1 -C 6 )alkyl.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is —H.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is not —H.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is -halo.
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 14 is —(C 1 -C 6 )alkyl, -halo, —C(halo) 3 , —OC(halo) 3 , —OR 7 , —N(R 7 ) 2 , —SO 2 R 7 , or —SO 2 C(halo) 3 .
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • each R 14 is independently —(C 1 -C 6 )alkyl, -halo, —C(halo) 3 , —OC(halo) 3 , —OR 7 , —N(R 7 ) 2 , —SO 2 R 7 , or —SO 2 C(halo) 3 .
  • the invention encompasses compounds of formula I.4:
  • X is O, S, N—CN, N—OH, or N—OR 10 ;
  • W is N or C
  • R 4 is absent, otherwise R 4 is —H, —OH, —OCF 3 , -halo, —(C 1 -C 6 )alkyl, —CH 2 OH, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 F, —CH(halo) 2 , —CF 3 , —OR 10 , —SR 10 , —COOH, —COOR 10 , —C(O)R 10 , —C(O)H, —OC(O)R 10 , —OC(O)NHR 10 , —NHC(O)R 13 , —CON(R 13 ) 2 , —S(O) 2 R 10 , or —NO 2 ;
  • R 10 is —(C 1 -C 4 )alkyl
  • each R 13 is independently: —H, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkenyl, —(C 1 -C 4 )alkynyl, or -phenyl;
  • c is the integer 0, 1, or 2;
  • Y 1 , Y 2 , Y 3 are independently C, N, or O;
  • Y 1 , Y 2 , or Y 3 can be 0, and for each Y 1 , Y 2 , and Y 3 that is N, the N is bonded to one R 21 group, and for each Y 1 , Y 2 , and Y 3 that is C, the C is bonded to two R 20 groups, provided that there are no more than a total of two (C 1 -C 6 )alkyl groups substituted on all of Y 1 , Y 2 , and Y 3 ;
  • R 12a and R 12b are independently —H or —(C 1 -C 6 )alkyl
  • E is ⁇ O, ⁇ S, ⁇ C(C 1 -C 5 )alkyl, ⁇ C(C 1 -C 5 )alkenyl, ⁇ NH(C 1 -C 6 )alkyl, or ⁇ N—OR 20 ;
  • R 1 is —H, -halo, —(C 1 -C 4 )alkyl, —NO 2 , —CN, —OH, —OCH 3 , —NH 2 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
  • each R 2 is independently:
  • Z 1 is —H, —OR 7 , —SR 7 , —CH 2 —OR 7 , —CH 2 —SR 7 , —CH 2 —N(R 20 ) 2 , or -halo;
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo;
  • each Z 3 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or -phenyl;
  • R 2 group is a group of formula Q, and provided that when Z 1 is —OR 7 or —SR 7 , then Z 2 is not -halo;
  • each R 3 is independently:
  • each R 7 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )hydroxyalkyl, —(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-N(R 20 ) 2 , or —CON(R 20 ) 2 ;
  • each R 8 and R 9 are independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH 2 C(halo) 3 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), —O—CN, —OH, -halo, —N 3 , —NO 2 , —CH ⁇ NR 7 , —N(R 7 ) 2 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(
  • each R 11 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH ⁇ NR 7 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , or —OC(O)OR 7 ;
  • each R 14 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, —(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), -(3- to 7-membered)heterocycle, —(C 1 -C 6 )haloalkyl, —(C 2 -C 6 )haloalkenyl, —(C 2 -C 6 )haloalkynyl, —(C 2 -C 6 )hydroxyalkenyl, —(C 2 -C 6 )hydroxyalkyny
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl
  • each R 21 is independently —H, —(C 1 -C 6 )alkyl
  • each halo is independently —F, —Cl, —Br, or —I;
  • n is the integer 1, 2, or 3;
  • p is the integer 1 or 2;
  • each b is independently the integer 1 or 2;
  • q is the integer 0, 1, 2, 3, or 4;
  • r is the integer 0, 1, 2, 3, 4, 5, or 6;
  • s is the integer 0, 1, 2, 3, 4, or 5;
  • t is the integer 0, 1, 2, or 3;
  • n is the integer 0, 1, or 2.
  • E is ⁇ O, ⁇ S, ⁇ CH(C 1 -C 5 )alkyl, ⁇ CH(C 1 -C 5 )alkenyl, or ⁇ N—OR 20 .
  • E is ⁇ O, ⁇ S, or ⁇ N—OR 20 .
  • the invention encompasses compounds of formula I.3:
  • X is O, S, N—CN, N—OH, or N—OR 10 ;
  • W is N or C
  • R 4 is absent, otherwise R 4 is —H, —OH, —OCF 3 , -halo, —(C 1 -C 6 )alkyl, —CH 2 OH, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 F, —CH(halo) 2 , —CF 3 , —OR 10 , —SR 10 , —COOH, —COOR 10 , —C(O)R 10 , —C(O)H, —OC(O)R 10 , —OC(O)NHR 10 , —NHC(O)R 13 , —CON(R 13 ) 2 , —S(O) 2 R 10 , or —NO 2 ;
  • R 10 is —(C 1 -C 4 )alkyl
  • each R 13 is independently: —H, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkenyl, —(C 1 -C 4 )alkynyl, or -phenyl;
  • c is the integer 0, 1, or 2;
  • Y 1 , Y 2 , Y 3 are independently C or N;
  • R 12a and R 12b are independently —H or —(C 1 -C 6 )alkyl
  • E is ⁇ O, ⁇ S, ⁇ C(C 1 -C 5 )alkyl, ⁇ C(C 1 -C 5 )alkenyl, ⁇ NH(C 1 -C 6 )alkyl, or ⁇ N—OR 20 ;
  • R 1 is —H, -halo, —(C 1 -C 4 )alkyl, —NO 2 , —CN, —OH, —OCH 3 , —NH 2 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
  • each R 2 is independently:
  • Z 1 is —H, —OR 7 , —SR 7 , —CH 2 —OR 7 , —CH 2 —SR 7 , —CH 2 —N(R 20 ) 2 , or -halo;
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo;
  • each Z 3 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or -phenyl;
  • R 2 group is a group of formula Q, and provided that when Z 1 is —OR 7 or —SR 7 , then Z 2 is not -halo;
  • each R 3 is independently:
  • each R 7 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )hydroxyalkyl, —(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-N(R 20 ) 2 , or —CON(R 20 ) 2 ;
  • each R 8 and R 9 are independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH 2 C(halo) 3 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), —O—CN, —OH, -halo, —N 3 , —NO 2 , —CH ⁇ NR 7 , —N(R 7 ) 2 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(
  • each R 11 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH ⁇ NR 7 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , or —OC(O)OR 7 ;
  • each R 14 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, —(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), -(3- to 7-membered)heterocycle, —(C 1 -C 6 )haloalkyl, —(C 2 -C 6 )haloalkenyl, —(C 2 -C 6 )haloalkynyl, —(C 2 -C 6 )hydroxyalkenyl, —(C 2 -C 6 )hydroxyalkyny
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl
  • each halo is independently —F, —Cl, —Br, or —I;
  • n is the integer 1, 2, or 3;
  • p is the integer 1 or 2;
  • each b is independently the integer 1 or 2;
  • q is the integer 0, 1, 2, 3, or 4;
  • r is the integer 0, 1, 2, 3, 4, 5, or 6;
  • s is the integer 0, 1, 2, 3, 4, or 5;
  • t is the integer 0, 1, 2, or 3;
  • n is the integer 0, 1, or 2.
  • E is ⁇ O, ⁇ S, ⁇ CH(C 1 -C 5 )alkyl, ⁇ CH(C 1 -C 5 )alkenyl, or ⁇ N—OR 20 .
  • E is ⁇ O, ⁇ S, or ⁇ N—OR 20 .
  • the invention encompasses compounds of formula I.2:
  • X is O, S, N—CN, N—OH, or N—OR 10 ;
  • W is N or C
  • R 4 is absent, otherwise R 4 is —H, —OH, —OCF 3 , -halo, —(C 1 -C 6 )alkyl, —CH 2 OH, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 F, —CH(halo) 2 , —CF 3 , —OR 10 , —SR 10 , —COOH, —COOR 10 , —C(O)R 10 , —C(O)H, —OC(O)R 10 , —OC(O)NHR 10 , —NHC(O)R 13 , —CON(R 13 ) 2 , —S(O) 2 R 10 , or —NO 2 ;
  • R 10 is —(C 1 -C 4 )alkyl
  • each R 13 is independently: —H, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkenyl, —(C 1 -C 4 )alkynyl, or -phenyl;
  • c is the integer 0, 1, or 2;
  • Y 1 , Y 2 , Y 3 are independently C or N;
  • R 12a and R 12b are independently —H or —(C 1 -C 6 )alkyl
  • E is ⁇ O, ⁇ S, ⁇ C(C 1 -C 5 )alkyl, ⁇ C(C 1 -C 5 )alkenyl, ⁇ NH(C 1 -C 6 )alkyl, or ⁇ N—OR 20 ;
  • R 1 is —H, -halo, —(C 1 -C 4 )alkyl, —NO 2 , —CN, —OH, —OCH 3 , —NH 2 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
  • each R 2 is independently:
  • Z 1 is —H, —OR 7 , —SR 7 , —CH 2 —OR 7 , —CH 2 —SR 7 , —CH 2 —N(R 20 ) 2 , or -halo;
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo;
  • each Z 3 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or -phenyl;
  • R 2 group is a group of formula Q, and provided that when Z 1 is —OR 7 or —SR 7 , then Z 2 is not -halo;
  • each R 3 is independently:
  • each R 7 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )hydroxyalkyl, —(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-N(R 20 ) 2 , or —CON(R 20 ) 2 ;
  • each R 8 and R 9 are independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH 2 C(halo) 3 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), —O—CN, —OH, -halo, —N 3 , —NO 2 , —CH ⁇ NR 7 , —N(R 7 ) 2 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(
  • each R 11 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH ⁇ NR 7 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , or —OC(O)OR 7 ;
  • each R 14 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, —(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), -(3- to 7-membered)heterocycle, —(C 1 -C 6 )haloalkyl, —(C 2 -C 6 )haloalkenyl, —(C 2 -C 6 )haloalkynyl, —(C 2 -C 6 )hydroxyalkenyl, —(C 2 -C 6 )hydroxyalkyny
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl
  • each halo is independently —F, —Cl, —Br, or —I;
  • n is the integer 1, 2, or 3;
  • p is the integer 1 or 2;
  • each b is independently the integer 1 or 2;
  • q is the integer 0, 1, 2, 3, or 4;
  • r is the integer 0, 1, 2, 3, 4, 5, or 6;
  • s is the integer 0, 1, 2, 3, 4, or 5;
  • t is the integer 0, 1, 2, or 3;
  • n is the integer 0, 1, or 2.
  • E is ⁇ O, ⁇ S, ⁇ CH(C 1 -C 5 )alkyl, ⁇ CH(C 1 -C 5 )alkenyl, or ⁇ N—OR 20 .
  • E is ⁇ O, ⁇ S, or ⁇ N—OR 20 .
  • the invention encompasses compounds of formula I.1:
  • X is O, S, N—CN, N—OH, or N—OR 10 ;
  • W is N or C
  • R 4 is absent, otherwise R 4 is —H, —OH, —OCF 3 , -halo, —(C 1 -C 6 )alkyl, —CH 2 OH, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 F, —CH(halo) 2 , —CF 3 , —OR 10 , —SR 10 , —COOH, —COOR 10 , —C(O)R 10 , —C(O)H, —OC(O)R 10 , —OC(O)NHR 10 , —NHC(O)R 13 , —CON(R 13 ) 2 , —S(O) 2 R 10 , or —NO 2 ;
  • R 10 is —(C 1 -C 4 )alkyl
  • each R 13 is independently: —H, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkenyl, —(C 1 -C 4 )alkynyl, or -phenyl;
  • c is the integer 0, 1, or 2;
  • Y 1 , Y 2 , Y 3 are independently C or N;
  • R 12a and R 12b are independently —H or —(C 1 -C 6 )alkyl
  • E is ⁇ O, ⁇ S, ⁇ C(C 1 -C 5 )alkyl, ⁇ C(C 1 -C 5 )alkenyl, ⁇ NH(C 1 -C 6 )alkyl, or ⁇ N—OR 20 ;
  • R 1 is —H, -halo, —(C 1 -C 4 )alkyl, —NO 2 , —CN, —OH, —OCH 3 , —NH 2 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
  • each R 2 is independently:
  • Z 1 is —H, —OR 7 , —SR 7 , —CH 2 —OR 7 , —CH 2 —SR 7 , —CH 2 —N(R 20 ) 2 , or -halo;
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo;
  • each Z 3 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or -phenyl;
  • R 2 group is a group of formula Q, and provided that when Z 1 is —OR 7 or —SR 7 , Z 2 in not -halo;
  • each R 3 is independently:
  • each R 7 is independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )hydroxyalkyl, —(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-N(R 20 ) 2 , or —CON(R 20 ) 2 ;
  • each R 8 and R 9 are independently —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH 2 C(halo) 3 , —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), —O—CN, —OH, -halo, —N 3 , —NO 2 , —CH ⁇ NR 7 , —N(R 7 ) 2 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(
  • each R 11 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH ⁇ NR 7 , —NR 7 OH, —OR 7 , —C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , or —OC(O)OR 7 ;
  • each R 14 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, —(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), -(3- to 7-membered)heterocycle, —(C 1 -C 6 )haloalkyl, —(C 2 -C 6 )haloalkenyl, —(C 2 -C 6 )haloalkynyl, —(C 2 -C 6 )hydroxyalkenyl, —(C 2 -C 6 )hydroxyalkyny
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl
  • each halo is independently —F, —Cl, —Br, or —I;
  • n is the integer 1, 2, or 3;
  • p is the integer 1 or 2;
  • each b is independently the integer 1 or 2;
  • q is the integer 0, 1, 2, 3, or 4;
  • r is the integer 0, 1, 2, 3, 4, 5, or 6;
  • s is the integer 0, 1, 2, 3, 4, or 5;
  • E is ⁇ O, ⁇ S, ⁇ CH(C 1 -C 5 )alkyl, ⁇ CH(C 1 -C 5 )alkenyl, or ⁇ N—OR 20 .
  • E is ⁇ O, ⁇ S, or ⁇ N—OR 20 .
  • the compound of formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Aqueous solubility of compounds is often a desirable feature.
  • aqueous solubility of a compound permits that compound to be more easily formulated into a variety of dosage forms that may be administered to an animal.
  • Aqueous solubility increases the likelihood that a compound will not precipitate in an animal's blood, and increases the ability to predict exposure at the target sight of the compound.
  • Compounds of formula I are highly soluble in aqueous solution.
  • compound 200 is insoluble in aqueous solution, i.e., has an aqueous solubility ⁇ 0.1 ⁇ M.
  • the aqueous solubility at pH 6.8, in ⁇ M, of compounds of formula I F2, E6, F6, and G2 is 3.0, 9.0, 9.2, and 38.2, respectively.
  • the aqueous solubility at pH 1.2, in ⁇ M, of compounds of formula I F2, E6, F6 and G2 is 1.0, 27.2, >50 and >50, respectively.
  • the aqueous solubility at either pH 6.8 or pH 1.2 of each of compounds of formula I G6, H6, J2, and Z1 is >50 ⁇ M.
  • the following compounds are aqueous insoluble at pH 6.8: 203, 207, 200, and 208.
  • the following compounds have very low aqueous solubility at pH 6.8: 209, 210, 211, 212, 213, 214, and 215 have aqueous solubility, in ⁇ M, of 1.0, 0.4, 0.4, 1.9, 0.8, 1.8, and 0.6, respectively.
  • the aqueous solubility, in ⁇ M, at pH 1.2 of compounds 209, 210, 211, 212, 213, 214 and 215 is 9.3, 2.0, 1.3, 10.3, 39.6, >50 and 9.6, respectively.
  • the aqueous solubility at pH 6.8, in ⁇ M, of compounds of formula I N1, F1, C1, Y3, and U3 is 28.0, 22.6, 15.7, 17.4, and 26.4, respectively.
  • compounds of formula I N1, F1, C1, Y3 and U3 all have an aqueous solubility of >50 ⁇ M.
  • the aqueous solubility, at either pH 6.8 or pH 1.2 is >50 ⁇ M for each of the following compounds of formula I: H1, N6, Z1, S1, E2, and U1.
  • compounds of formula I are compounds of formula IA′:
  • a compound of formula IA′ is a pharmaceutically acceptable derivative of a compound of formula IA′.
  • a compound of formula IA′ is a compound of formula IA′ wherein the derivative is a pharmaceutically acceptable salt.
  • a compound of formula IA′ is a pharmaceutically acceptable salt of a compound of formula IA′.
  • Ar 1 is a pyridyl group.
  • Ar 1 is a pyrimidinyl group.
  • Ar 1 is a pyrazinyl group.
  • Ar 1 is pyridazinyl group.
  • W is C.
  • W is N.
  • X is O.
  • X is S.
  • X is N—CN.
  • X is N—OH.
  • X is N—OR 10 .
  • Ar 2 is a benzoimidazolyl group.
  • Ar 2 is a benzothiazolyl group.
  • Ar 2 is a benzooxazolyl group.
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • n or p is 1.
  • n or p is 2.
  • n 3.
  • n 2
  • each R 3 is independently —H, or —(C 1 -C 6 )alkyl.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R 8 groups, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with an R 8 group, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted or substituted with an R 8 group, and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted and which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge.
  • two R 3 groups together form a (C 2 )bridge, a —HC ⁇ CH— bridge, or a (C 3 )bridge each of which is unsubstituted.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R 8 groups, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 6 )bridge, which is unsubstituted or substituted with an R 8 group, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 6 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted or substituted with an R 8 group, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 -C 3 )bridge, which is unsubstituted, which bridge optionally contains —HC ⁇ CH— within the (C 2 -C 3 )bridge, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a (C 2 )bridge, a —HC ⁇ CH— bridge, or a (C 3 )bridge each of which is unsubstituted, and which bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups together form a —CH 2 —N(R a )—CH 2 — bridge (B1), a
  • R a is —H, —(C 1 -C 6 )alkyl, —(C 3 -C 8 )cycloalkyl, —CH 2 —C(O)—R c , —(CH 2 )—C(O)—OR c , —(CH 2 )—C(O)—N(R c ) 2 , —(CH 2 ) 2 —O—R c , —(CH 2 ) 2 —S(O) 2 —N(R c ) 2 , or —(CH 2 ) 2 —N(R c )S(O) 2 —R c ;
  • R b is:
  • each R 1 is independently —H or —(C 1 -C 4 )alkyl
  • the B1, B2, or B3 bridge joins positions 2 and 6 of the piperidine, 1,2,3,6-tetrahydropyridine or piperazine ring.
  • two R 3 groups form a bicyclo group to give one of the following structures
  • n 1
  • n 0.
  • s or q is 0.
  • s or q is 1.
  • s or q is 2.
  • R 1 is —H.
  • R 1 is -halo
  • R 1 is —Cl
  • R 1 is —F.
  • R 1 is —CH 3 .
  • R 1 is —NO 2 .
  • R 1 is —CN.
  • R 1 is —OH.
  • R 1 is —OCH 3 .
  • R 1 is —NH 2 .
  • R 1 is —C(halo) 3 .
  • R 1 is —CF 3 .
  • R 1 is —CH(halo) 2 .
  • R 1 is —CH 2 (halo).
  • Ar 1 is a pyridyl group and n is 1.
  • Ar 1 is a pyrazinyl group and p is 1.
  • Ar 1 is a pyrimidinyl group and p is 1.
  • Ar 1 is a pyridazinyl group and p is 1.
  • R 2 when n and p are 1, then R 2 must be Q.
  • Z 1 is —H.
  • Z 1 is —OH.
  • Z 1 is —OCH 3 .
  • Z 1 is —CH 2 OH.
  • Z 2 is —CH 2 —OR 7 .
  • Z 2 is —CH 2 OH.
  • Z 2 is —H, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, -phenyl, or -halo.
  • Z 2 is —H.
  • Z 2 is —CH 3 .
  • Z 3 is —H.
  • Z 3 is —CH 3 .
  • m is 1 and R 3 is —(C 1 -C 6 )alkyl.
  • m is 1 and R 3 is —CH 3 or —CH 2 CH 3 .
  • m is 1 and R 3 is —CH 3 .
  • m is 1 and R 3 is —CH 2 OH.
  • n 0.
  • R 4 is —OH.
  • R 4 is —OCF 3 .
  • R 4 is -halo
  • R 4 is —F.
  • R 4 is —Cl
  • R 4 is —(C 1 -C 6 )alkyl.
  • R 4 is —CH 3 .
  • R 4 is —CH 2 OH.
  • R 4 is —CH 2 Cl.
  • R 4 is —CH 2 Br.
  • R 4 is —CH 2 I.
  • R 4 is —CH 2 F.
  • R 4 is —CH(halo) 2 .
  • R 4 is —CF 3 .
  • R 4 is —NO 2 .
  • R 4 is —OR 10 .
  • R 4 is —SR 10 .
  • R 4 is —C(O)R 10 .
  • R 4 is —COOH
  • R 4 is —C(O)H.
  • R 4 is —COOR 10 .
  • R 4 is —OC(O)R 10 .
  • R 4 is —SO 2 R 10 .
  • R 4 is —OC(O)NHR 10 .
  • R 4 is —NHC(O)R 13 .
  • R 4 is —CON(R 13 ) 2 .
  • each R 20 is independently —H or —(C 1 -C 6 )alkyl.
  • each R 20 is —H.
  • each R 20 is —(C 1 -C 6 )alkyl.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is —H.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is not —H.
  • Ar 2 is a benzothiazolyl, benzoimidazolyl, or benzooxazolyl group; and at least one of R 8 and R 9 is -halo.
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 14 is —(C 1 -C 6 )alkyl, -halo, —C(halo) 3 , —OC(halo) 3 , —OR 7 , —N(R 7 ) 2 , —SO 2 R 7 , or —SO 2 C(halo) 3 .
  • Ar 2 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • each R 14 is independently —(C 1 -C 6 )alkyl, -halo, —C(halo) 3 , —OC(halo) 3 , —OR 7 , —N(R 7 ) 2 , —SO 2 R 7 , or —SO 2 C(halo) 3 .
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • R 4 is -halo, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • R 4 is —F, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • R 1 is -halo
  • R 4 is -halo
  • n or p is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • R 1 is —Cl
  • R 4 is —F
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • Ar 1 is a pyridyl group, wherein n is 1, and R 2 is Q.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl, Z 1 is —OH and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl, Z 1 is —OH and Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzooxazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl, Z 1 is —OH and Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzoimidazolyl, wherein at least one of R 8 or R 9 is not —H.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OH
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is phenyl, wherein s is 0 or 1.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl, Z 1 is —OH and Ar 2 is phenyl, wherein s is 2.
  • R 1 is -halo
  • R 4 is -halo
  • Ar 1 is a pyridyl group, wherein n is 1, R 2 is Q, and Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is phenyl, wherein s is 2.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • the dashed line is a double bond, n or p is 1, R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • n or p is 1
  • R 2 is Q
  • Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OR 7 .
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Z 1 is —CH 2 OH.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl, Z 1 is —OH and Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 1 -C 6 )alkyl
  • Z 1 is —CH 2 OH
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
  • R 20 is —(C 3 -C 8 )cycloalkyl
  • Z 1 is —OR 7
  • Ar 2 is benzothiazolyl, wherein at least one of R 8 or R 9 is not a —H.
  • the dashed line is a double bond
  • R 1 is -halo
  • Ar 1 is a pyridyl group
  • n is 1
  • R 2 is Q, wherein Q is
US12/110,089 2007-04-27 2008-04-25 Trpv1 antagonists including sulfonamide substituent and uses thereof Abandoned US20090170867A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/110,089 US20090170867A1 (en) 2007-04-27 2008-04-25 Trpv1 antagonists including sulfonamide substituent and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92666107P 2007-04-27 2007-04-27
US93003607P 2007-05-11 2007-05-11
US93700307P 2007-06-21 2007-06-21
US96240907P 2007-07-27 2007-07-27
US12/110,089 US20090170867A1 (en) 2007-04-27 2008-04-25 Trpv1 antagonists including sulfonamide substituent and uses thereof

Publications (1)

Publication Number Publication Date
US20090170867A1 true US20090170867A1 (en) 2009-07-02

Family

ID=39688846

Family Applications (8)

Application Number Title Priority Date Filing Date
US12/110,089 Abandoned US20090170867A1 (en) 2007-04-27 2008-04-25 Trpv1 antagonists including sulfonamide substituent and uses thereof
US12/110,155 Active 2029-05-26 US8476277B2 (en) 2007-04-27 2008-04-25 TRPV1 antagonists including dihydroxy substituent and uses thereof
US12/110,212 Abandoned US20090176796A1 (en) 2007-04-27 2008-04-25 Trpv1 antagonists including amide substituent and uses thereof
US13/396,450 Active US8575199B2 (en) 2007-04-27 2012-02-14 Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists
US13/852,913 Active US8889690B2 (en) 2007-04-27 2013-03-28 TRPV1 antagonists including dihydroxy substituent and uses thereof
US14/498,724 Active US9365563B2 (en) 2007-04-27 2014-09-26 TRPV1 antagonists including dihydroxy substituent and uses thereof
US15/179,612 Active US9878991B2 (en) 2007-04-27 2016-06-10 TRPV1 antagonists including dihydroxy substituent and uses thereof
US15/864,750 Active US10584110B2 (en) 2007-04-27 2018-01-08 TRPV1 antagonists including dihydroxy substituent and uses thereof

Family Applications After (7)

Application Number Title Priority Date Filing Date
US12/110,155 Active 2029-05-26 US8476277B2 (en) 2007-04-27 2008-04-25 TRPV1 antagonists including dihydroxy substituent and uses thereof
US12/110,212 Abandoned US20090176796A1 (en) 2007-04-27 2008-04-25 Trpv1 antagonists including amide substituent and uses thereof
US13/396,450 Active US8575199B2 (en) 2007-04-27 2012-02-14 Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists
US13/852,913 Active US8889690B2 (en) 2007-04-27 2013-03-28 TRPV1 antagonists including dihydroxy substituent and uses thereof
US14/498,724 Active US9365563B2 (en) 2007-04-27 2014-09-26 TRPV1 antagonists including dihydroxy substituent and uses thereof
US15/179,612 Active US9878991B2 (en) 2007-04-27 2016-06-10 TRPV1 antagonists including dihydroxy substituent and uses thereof
US15/864,750 Active US10584110B2 (en) 2007-04-27 2018-01-08 TRPV1 antagonists including dihydroxy substituent and uses thereof

Country Status (28)

Country Link
US (8) US20090170867A1 (ko)
EP (3) EP2604598B1 (ko)
JP (2) JP5462784B2 (ko)
KR (2) KR20130004524A (ko)
CN (1) CN101932570B (ko)
AR (1) AR066146A1 (ko)
AU (1) AU2008243874B2 (ko)
BR (1) BRPI0809795A2 (ko)
CA (3) CA2833209C (ko)
CO (1) CO6241153A2 (ko)
CY (1) CY1115262T1 (ko)
DK (1) DK2142529T3 (ko)
ES (2) ES2571533T3 (ko)
HK (2) HK1139949A1 (ko)
HR (1) HRP20140279T1 (ko)
IL (2) IL201688A (ko)
ME (1) ME02123B (ko)
MX (1) MX2009011600A (ko)
MY (1) MY148657A (ko)
NZ (1) NZ580266A (ko)
PE (2) PE20130325A1 (ko)
PH (1) PH12013500848B1 (ko)
PL (1) PL2142529T3 (ko)
PT (1) PT2142529E (ko)
RS (1) RS53212B (ko)
TW (1) TWI362930B (ko)
UY (1) UY31050A1 (ko)
WO (1) WO2008132600A2 (ko)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170868A1 (en) * 2007-04-27 2009-07-02 Purdue Pharma L. P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US20100120862A1 (en) * 2008-10-24 2010-05-13 Laykea Tafesse Monocyclic compounds and their use as trpv1 ligands
US20100130499A1 (en) * 2008-10-24 2010-05-27 Laykea Tafesse Bicycloheteroaryl compounds and their use as trpv1 ligands
US20100137306A1 (en) * 2008-10-24 2010-06-03 Laykea Tafesse Heterocyclic trpv1 receptor ligands
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
WO2012176061A1 (en) 2011-06-22 2012-12-27 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9017722B2 (en) 2001-01-29 2015-04-28 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US20160024009A1 (en) * 2013-03-06 2016-01-28 Ario Pharma Limited Novel Sulfonamide TRPA1 Receptor Antagonists
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
US20210220343A1 (en) * 2013-09-24 2021-07-22 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151689A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2797708C (en) 2010-05-04 2016-08-16 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
WO2011162409A1 (en) * 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
EP2654751B1 (en) 2010-12-22 2016-11-23 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
US20150011528A1 (en) * 2011-09-23 2015-01-08 Yuhan Corporation Phenylimide-containing benzothiazole derivative of its salt and pharmaceutical composition comprising the same
MY194911A (en) 2012-06-04 2022-12-22 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
JP6249517B2 (ja) * 2012-11-08 2017-12-20 花王株式会社 体感温度低減用外用剤
JP6308881B2 (ja) * 2014-06-11 2018-04-11 保土谷化学工業株式会社 電荷制御剤およびそれを用いたトナー
WO2016141068A1 (en) 2015-03-03 2016-09-09 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
CN113292485B (zh) * 2021-06-08 2023-10-27 河南大学 苄基哌嗪脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用

Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en) * 1977-12-02 1983-10-11 Hoechst-Roussel Pharmaceuticals, Inc. Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
US4797419A (en) * 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US5059595A (en) * 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5138058A (en) * 1989-02-22 1992-08-11 Hoechst Aktiengesellschaft Piperazine substituted pyrimidine derivatives and physiologically tolerated salts thereof
US5354556A (en) * 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US5399574A (en) * 1990-06-07 1995-03-21 Burroughs Wellcome Co. Indolyl tetrahydropyridines for treating migraine
US5442064A (en) * 1992-10-12 1995-08-15 Dr. Karl Thomae Gmbh Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5529998A (en) * 1994-08-03 1996-06-25 Bayer Aktiengesellschaft Benzoxazolyl- and benzothiazolyloxazolidinones
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5639476A (en) * 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5674533A (en) * 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5837716A (en) * 1995-11-13 1998-11-17 Albany Medical College Analgesic heterocyclic compounds
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5990107A (en) * 1996-06-28 1999-11-23 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6051712A (en) * 1995-09-07 2000-04-18 Hoffmann-La Roche Inc. Piperidine derivatives having renin inhibiting activity
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040034061A1 (en) * 2000-07-05 2004-02-19 Atsuro Nakazato Tetrahydropyridino or piperidino heterocylic derivatives
US20040259912A1 (en) * 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US20050222410A1 (en) * 2002-04-27 2005-10-06 Stokes Elaine Sophie E Inhibitors of histone deacetylase
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20060052403A1 (en) * 2002-09-27 2006-03-09 Yoshiaki Isobe Novel adenine compound and use thereof
US20060128755A1 (en) * 2003-05-20 2006-06-15 Ajinomoto Co. Inc Amide derivative
US20060235004A1 (en) * 2003-03-13 2006-10-19 Abbot Gmbh & Co. Kg Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands
US7129235B2 (en) * 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US20060293308A1 (en) * 2003-07-29 2006-12-28 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7279493B2 (en) * 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7343017B2 (en) * 1999-08-26 2008-03-11 American Technology Corporation System for playback of pre-encoded signals through a parametric loudspeaker system
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20080280916A1 (en) * 2003-07-30 2008-11-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7456180B2 (en) * 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7514436B2 (en) * 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US20090105271A1 (en) * 2007-09-19 2009-04-23 Esther Martinborough Pyridyl sulfonamides as modulators of ion channels
US7528134B2 (en) * 2002-05-23 2009-05-05 Abbott Laboratories Inc. Acetamides and benzamides that are useful in treating sexual dysfunction
US7538121B2 (en) * 2002-02-15 2009-05-26 Glaxo Group Limited Vanilloid receptor modulators
US20090143302A1 (en) * 2005-06-14 2009-06-04 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US7572812B2 (en) * 2003-07-24 2009-08-11 Purdue Pharma, L.P., Usa Therapeutic agents useful for treating pain
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
US7632950B2 (en) * 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
US20100022530A1 (en) * 2006-12-21 2010-01-28 Merck Patent Gmbh Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein
US7683063B2 (en) * 2003-06-12 2010-03-23 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7776861B2 (en) * 2003-07-24 2010-08-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3440141A1 (de) 1984-11-02 1986-05-07 Heiner Dipl.-Chem. Dr. 8000 München Eckert Verwendung von kohlensaeure-bis-trichlormethylester als proreagens fuer phosgen
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPS6289679U (ko) 1985-11-22 1987-06-08
US4866197A (en) 1987-12-23 1989-09-12 American Home Products Corporation Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters
JP3191429B2 (ja) 1992-09-02 2001-07-23 富士通テン株式会社 電子機器の挿排装置
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
US5798360A (en) * 1996-08-01 1998-08-25 Isis Pharmaceuticals, Inc. N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
JP4444493B2 (ja) * 1997-08-20 2010-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用
JPH11199573A (ja) 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd ５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
EP1087962A4 (en) 1998-06-19 2001-10-04 Lilly Co Eli PRODUCTION OF HETEROARYL COMPOUNDS
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
CA2345146C (en) * 1998-09-22 2010-02-23 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivative
JP2002535256A (ja) 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 化合物および方法
GB9907097D0 (en) * 1999-03-26 1999-05-19 Novartis Ag Organic compounds
MXPA01009871A (es) * 1999-04-01 2002-04-24 Pfizer Prod Inc Aminopiridinas como inhibidores de la sorbitol deshidrogenasa.
WO2000069816A1 (en) 1999-05-17 2000-11-23 Eli Lilly And Company Metabotropic glutamate receptor antagonists
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
HUP0300359A2 (hu) 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
US20020183362A1 (en) 2000-04-25 2002-12-05 Pharmacia Corporation 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
BR0112395A (pt) * 2000-06-21 2003-07-08 Hoffmann La Roche Derivados de benzotiazol
US7060331B2 (en) * 2000-07-13 2006-06-13 Merck Patent Gmbh Chiral compounds 1
BR0112631A (pt) * 2000-07-20 2003-09-23 Neurogen Corp Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
WO2002032411A2 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
ES2230378T3 (es) * 2000-11-30 2005-05-01 Pfizer Products Inc. Combinacion de agonistas de gaba e inhibidores de sorbitol deshidrogenasa.
TWI239945B (en) 2000-12-15 2005-09-21 Japan Science & Tech Agency Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof and methods for producing the same
US7193113B2 (en) * 2000-12-15 2007-03-20 Japan Science And Technology Corporation Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof, and methods for producing the same
US20030232996A1 (en) 2001-04-20 2003-12-18 Brown David L Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
US20040038982A1 (en) * 2001-07-13 2004-02-26 Bondinell William E. Compounds and methods
JP2003095951A (ja) 2001-09-25 2003-04-03 Sumitomo Pharmaceut Co Ltd 慢性関節リウマチ治療剤
US20040259917A1 (en) 2001-12-19 2004-12-23 Cosford Nicholas D.P. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
DE60332316D1 (de) * 2002-02-01 2010-06-10 Euro Celtique Sa 2-piperazinpyridine für die schmerzbehandlung
ES2322252T3 (es) * 2002-03-13 2009-06-18 Janssen Pharmaceutica Nv Aminoderivados como nuevos inhibidores de histona-desacetilasa.
CN1150176C (zh) * 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
WO2004002531A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
AU2003256922A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PL377215A1 (pl) * 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
ES2375134T3 (es) * 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1651606B1 (en) 2003-07-30 2012-10-24 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
WO2005037284A1 (en) 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
US20050130974A1 (en) * 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200626138A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083994A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
US20060116368A1 (en) * 2004-11-29 2006-06-01 Calvo Raul R 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
EP1863771B1 (en) * 2005-03-14 2012-11-07 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007082731A1 (en) 2006-01-18 2007-07-26 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2644069A1 (en) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2008128072A2 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
AU2008246202B2 (en) * 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
PE20130325A1 (es) 2007-04-27 2013-03-18 Purdue Pharma Lp Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20110046142A1 (en) 2007-06-13 2011-02-24 Northeastern University Antibiotic compounds
JP2010531360A (ja) 2007-06-28 2010-09-24 インターベット インターナショナル ベー． フェー． Ｃｂ１拮抗剤としてのピペラジンの使用
JP2010532382A (ja) 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのｎｍｄａ受容体拮抗薬
JP2010535812A (ja) * 2007-08-09 2010-11-25 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬としてのテトラヒドロピリジンカルボキサミド誘導体
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2009045382A1 (en) 2007-10-04 2009-04-09 Merck & Co., Inc. Substituted aryl sulfone derivatives as calcium channel blockers
CA2708364A1 (en) 2007-12-11 2009-06-18 Efrat Ben-Zeev Carboxamide compounds and their use as chemokine receptor agonists
JP2009249346A (ja) 2008-04-08 2009-10-29 Fujifilm Corp ピリジン骨格を有する血液脳関門透過性化合物
WO2010010458A1 (en) 2008-07-21 2010-01-28 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof

Patent Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en) * 1977-12-02 1983-10-11 Hoechst-Roussel Pharmaceuticals, Inc. Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
US5354556A (en) * 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US4797419A (en) * 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5138058A (en) * 1989-02-22 1992-08-11 Hoechst Aktiengesellschaft Piperazine substituted pyrimidine derivatives and physiologically tolerated salts thereof
US5059595A (en) * 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5399574A (en) * 1990-06-07 1995-03-21 Burroughs Wellcome Co. Indolyl tetrahydropyridines for treating migraine
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5639476A (en) * 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5442064A (en) * 1992-10-12 1995-08-15 Dr. Karl Thomae Gmbh Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674533A (en) * 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US5529998A (en) * 1994-08-03 1996-06-25 Bayer Aktiengesellschaft Benzoxazolyl- and benzothiazolyloxazolidinones
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6051712A (en) * 1995-09-07 2000-04-18 Hoffmann-La Roche Inc. Piperidine derivatives having renin inhibiting activity
US5837716A (en) * 1995-11-13 1998-11-17 Albany Medical College Analgesic heterocyclic compounds
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5990107A (en) * 1996-06-28 1999-11-23 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US7343017B2 (en) * 1999-08-26 2008-03-11 American Technology Corporation System for playback of pre-encoded signals through a parametric loudspeaker system
US20040034061A1 (en) * 2000-07-05 2004-02-19 Atsuro Nakazato Tetrahydropyridino or piperidino heterocylic derivatives
US20040259912A1 (en) * 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US7538121B2 (en) * 2002-02-15 2009-05-26 Glaxo Group Limited Vanilloid receptor modulators
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20050222410A1 (en) * 2002-04-27 2005-10-06 Stokes Elaine Sophie E Inhibitors of histone deacetylase
US7528134B2 (en) * 2002-05-23 2009-05-05 Abbott Laboratories Inc. Acetamides and benzamides that are useful in treating sexual dysfunction
US7279493B2 (en) * 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080153835A1 (en) * 2002-06-28 2008-06-26 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080200472A1 (en) * 2002-07-26 2008-08-21 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20060052403A1 (en) * 2002-09-27 2006-03-09 Yoshiaki Isobe Novel adenine compound and use thereof
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20060235004A1 (en) * 2003-03-13 2006-10-19 Abbot Gmbh & Co. Kg Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands
US20060128755A1 (en) * 2003-05-20 2006-06-15 Ajinomoto Co. Inc Amide derivative
US7683063B2 (en) * 2003-06-12 2010-03-23 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US7129235B2 (en) * 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US7776861B2 (en) * 2003-07-24 2010-08-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7572812B2 (en) * 2003-07-24 2009-08-11 Purdue Pharma, L.P., Usa Therapeutic agents useful for treating pain
US20060293308A1 (en) * 2003-07-29 2006-12-28 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7514436B2 (en) * 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7456180B2 (en) * 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20080280916A1 (en) * 2003-07-30 2008-11-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7632950B2 (en) * 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
US20090143302A1 (en) * 2005-06-14 2009-06-04 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20100022530A1 (en) * 2006-12-21 2010-01-28 Merck Patent Gmbh Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein
US20090105271A1 (en) * 2007-09-19 2009-04-23 Esther Martinborough Pyridyl sulfonamides as modulators of ion channels

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561217B2 (en) 2001-01-29 2017-02-07 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US9017722B2 (en) 2001-01-29 2015-04-28 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US8575199B2 (en) 2007-04-27 2013-11-05 Purdue Pharma L.P. Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists
US10584110B2 (en) 2007-04-27 2020-03-10 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9878991B2 (en) 2007-04-27 2018-01-30 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US20090170868A1 (en) * 2007-04-27 2009-07-02 Purdue Pharma L. P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9365563B2 (en) 2007-04-27 2016-06-14 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US20090176796A1 (en) * 2007-04-27 2009-07-09 Purdue Pharma L. P. Trpv1 antagonists including amide substituent and uses thereof
US8476277B2 (en) 2007-04-27 2013-07-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US20100120862A1 (en) * 2008-10-24 2010-05-13 Laykea Tafesse Monocyclic compounds and their use as trpv1 ligands
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US20100130499A1 (en) * 2008-10-24 2010-05-27 Laykea Tafesse Bicycloheteroaryl compounds and their use as trpv1 ligands
US20100137306A1 (en) * 2008-10-24 2010-06-03 Laykea Tafesse Heterocyclic trpv1 receptor ligands
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
EP3173411A1 (en) 2011-06-22 2017-05-31 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2012176061A1 (en) 2011-06-22 2012-12-27 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US10450308B2 (en) 2011-06-22 2019-10-22 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9630959B2 (en) 2011-06-22 2017-04-25 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9873691B2 (en) 2011-08-10 2018-01-23 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9409864B2 (en) * 2013-03-06 2016-08-09 Ario Pharma Limited Sulfonamide TRPA1 receptor antagonists
US20160024009A1 (en) * 2013-03-06 2016-01-28 Ario Pharma Limited Novel Sulfonamide TRPA1 Receptor Antagonists
US20210220343A1 (en) * 2013-09-24 2021-07-22 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same

Also Published As

Publication number Publication date
JP2014015465A (ja) 2014-01-30
CA2756791A1 (en) 2008-11-06
HK1139949A1 (en) 2010-09-30
PT2142529E (pt) 2014-03-20
US9878991B2 (en) 2018-01-30
DK2142529T3 (da) 2014-02-10
AU2008243874A1 (en) 2008-11-06
RS53212B (en) 2014-08-29
TW200911249A (en) 2009-03-16
US10584110B2 (en) 2020-03-10
EP2604598B1 (en) 2016-04-06
UY31050A1 (es) 2008-07-03
KR20100005725A (ko) 2010-01-15
US20090176796A1 (en) 2009-07-09
US20090170868A1 (en) 2009-07-02
CA2833209C (en) 2016-06-28
ES2453947T3 (es) 2014-04-09
EP2142529A2 (en) 2010-01-13
CA2756791C (en) 2016-09-13
CA2685266C (en) 2014-01-28
CN101932570A (zh) 2010-12-29
KR20130004524A (ko) 2013-01-10
ME02123B (me) 2014-08-29
IL225521A0 (en) 2013-06-27
WO2008132600A3 (en) 2009-03-12
PL2142529T3 (pl) 2014-06-30
CA2685266A1 (en) 2008-11-06
US20120177570A1 (en) 2012-07-12
PE20130325A1 (es) 2013-03-18
JP2010525048A (ja) 2010-07-22
EP2604599A1 (en) 2013-06-19
EP2604598A1 (en) 2013-06-19
CA2833209A1 (en) 2013-11-13
US8889690B2 (en) 2014-11-18
US20150018366A1 (en) 2015-01-15
US20130338170A1 (en) 2013-12-19
US8476277B2 (en) 2013-07-02
TWI362930B (en) 2012-05-01
US9365563B2 (en) 2016-06-14
HK1184152A1 (zh) 2014-01-17
ES2571533T3 (es) 2016-05-25
HRP20140279T1 (hr) 2014-04-25
IL201688A (en) 2017-01-31
US8575199B2 (en) 2013-11-05
IL201688A0 (en) 2010-05-31
BRPI0809795A2 (pt) 2014-10-07
MY148657A (en) 2013-05-15
US20160355499A1 (en) 2016-12-08
AR066146A1 (es) 2009-07-29
AU2008243874B2 (en) 2012-01-19
CY1115262T1 (el) 2017-01-04
MX2009011600A (es) 2010-11-26
US20180208575A1 (en) 2018-07-26
CO6241153A2 (es) 2011-01-20
EP2142529B1 (en) 2013-12-25
PE20090422A1 (es) 2009-04-18
WO2008132600A2 (en) 2008-11-06
NZ580266A (en) 2012-03-30
PH12013500848A1 (en) 2015-05-18
CN101932570B (zh) 2014-11-26
JP5462784B2 (ja) 2014-04-02
PH12013500848B1 (en) 2015-05-18

Similar Documents

Publication Publication Date Title
US10584110B2 (en) TRPV1 antagonists including dihydroxy substituent and uses thereof
US9156830B2 (en) Heterocyclic compounds
CA2533509C (en) Piperidine compounds and pharmaceutical compositions containing them
US8759362B2 (en) Bicycloheteroaryl compounds and their use as TRPV1 ligands
US20130123239A1 (en) Compounds having trpv1 antagonistic activity and uses thereof
AU2011226773B2 (en) TRPV1 antagonists and uses thereof
AU2013213667A1 (en) TRPV1 antagonists and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHIONOGI & CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KUROSE, NORIYUKI;REEL/FRAME:021981/0288

Effective date: 20081208

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION